Alexion To Pay $25M To Settle Soliris Suit

Law360, New York (January 5, 2009, 12:00 AM EST) -- Biopharmaceutical firm Alexion Pharmaceuticals Inc. has agreed to pay $25 million to PDL BioPharma Inc. as part of a licensing deal that resolves PDL’s patent infringement suit over Alexion’s blood disorder treatment Soliris.

Under the settlement reached in late December, Alexion confirmed that its drug uses technology covered under PDL’s patents, and PDL agreed not to sue Alexion over other claims of the patents, clearing the way for Alexion to continue to commercialize Soliris.

The companies said the agreement wraps up PDL’s suit filed in March...
To view the full article, register now.